Compare FPF & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPF | EVMN |
|---|---|---|
| Founded | 2013 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 892.4M |
| IPO Year | N/A | N/A |
| Metric | FPF | EVMN |
|---|---|---|
| Price | $17.86 | $24.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $43.29 |
| AVG Volume (30 Days) | 133.1K | ★ 235.6K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.32 | $13.89 |
| 52 Week High | $19.75 | $33.20 |
| Indicator | FPF | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 54.04 |
| Support Level | N/A | $21.14 |
| Resistance Level | $18.88 | $25.50 |
| Average True Range (ATR) | 0.33 | 1.89 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 49.24 | 84.16 |
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.